Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05394350
Other study ID # 1088-002
Secondary ID MK-1088-0022021-
Status Terminated
Phase Phase 1/Phase 2
First received
Last updated
Start date July 7, 2022
Est. completion date September 7, 2023

Study information

Verified date September 2023
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.


Recruitment information / eligibility

Status Terminated
Enrollment 27
Est. completion date September 7, 2023
Est. primary completion date September 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: - Has a histologically- or cytologically-confirmed diagnosis of advanced/metastatic solid tumor by pathology report and have received, have been intolerant to, or have been ineligible for treatment known to confer clinical benefit - For metastatic castrate-resistant prostate cancer (mCRPC) only: (1) Must have previously received docetaxel, prior treatment with one other chemotherapy is allowed as well as up to 2 second-generation hormonal manipulations and (2) have prostate cancer progression within 6 months before screening, as determined by the investigator - If human immunodeficiency virus (HIV) positive, has well-controlled HIV on anti-retroviral therapy (ART) Exclusion Criteria: - Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention - Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years - Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis - Has an active infection requiring therapy - Has a history of interstitial lung disease - Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis - Has an active autoimmune disease that has required systemic treatment in the past 2 years - Has concurrent active Hepatitis B and Hepatitis C virus infection - Has HIV with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease - Has not fully recovered from any effects of major surgery without significant detectable infection - Has a history or current evidence of a gastrointestinal (GI) condition or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral medications - Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including NYHA Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability - Has a QTcF >470 msec - Has history of an allogeneic stem cell transplant or a solid organ transplant. - Has received prior systemic anticancer therapy including investigational agents within 4 weeks before allocation - Has received prior radiotherapy within 2 weeks of start of study intervention, or had radiation-related toxicities requiring corticosteroids - Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention - Has a "superscan" bone scan

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MK-1088
Oral Tablet
Biological:
Pembrolizumab
IV Infusion

Locations

Country Name City State
Canada Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 Quebec
Canada Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201) Toronto Ontario
Denmark Herlev and Gentofte Hospital ( Site 0501) Copenhagen Hovedstaden
Denmark Rigshospitalet ( Site 0500) Copenhagen Hovedstaden
Denmark Odense Universitetshospital ( Site 0502) Odense Syddanmark
Israel Rambam Health Care Campus-Oncology Division ( Site 0300) Haifa
Israel Hadassah Medical Center ( Site 0302) Jerusalem
Switzerland Ospedale Regionale Bellinzona e Valli ( Site 0400) Bellinzona Ticino
Switzerland Kantonsspital Graubünden-Medizin ( Site 0402) Chur Grisons
Switzerland Cantonal Hospital St.Gallen ( Site 0403) st.Gallen Sankt Gallen
United States University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0103) Miami Florida
United States Laura and Isaac Perlmutter Cancer Center ( Site 0102) New York New York
United States South Texas Accelerated Research Therapeutics (START) ( Site 0101) San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  Israel,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants experiencing a dose-limiting toxicity (DLT) A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). Number of participants who experience a DLT will be reported. Up to 21 days
Primary Number of participants experiencing an adverse event (AE) An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experienced an AE will be reported. Up to ~27 months
Primary Number of participants discontinuing study treatment due to an AE An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinued study treatment due to an AE will be reported. Up to ~24 months
Secondary Area under the plasma concentration-time curve (AUC) of MK-1088 AUC of MK-1088 determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported. Pre-dose and 1, 2, 4, and 8 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1; Pre-dose on Cycle 1 Day 2 and Cycle 2 Day 2; Pre-dose on Cycle 3, Cycle 4 and every 4 cycles up to ~27 months. Each cycle = 21 days
Secondary Maximum plasma concentration (Cmax) of MK-1088 Cmax of MK-1088 determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported. Pre-dose and 1, 2, 4, and 8 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1; Pre-dose on Cycle 1 Day 2 and Cycle 2 Day 2; Pre-dose on Cycle 3, Cycle 4 and every 4 cycles up to ~27 months. Each cycle = 21 days
Secondary Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by investigator ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by the investigator based on RECIST 1.1 will be reported. Up to ~3 years
Secondary ORR per Prostate Cancer Working Group (PCWG)-modified RECIST 1.1 as assessed by investigator ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per PCWG-modified RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by the investigator based on PCWG-modified RECIST 1.1 will be reported. Up to ~3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1